Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Globe Newswire•08/10/2026•16:30 ET
0
Key Highlights
- ➤SION-719 trial missed key activity endpoint; post hoc analysis showed 8.6 mmol/L sweat chloride reduction
- ➤SION-719 periods showed lower exposure for all three Trikafta components
- ➤Sionna plans SION-451 plus SION-2222 Phase 2a trial in Q1 2027
- ➤NBD1-stabilizer combinations improved CFTR function up to wild-type levels preclinically
Expert Statements
Gregory S. Sawicki, Director of the Cystic Fibrosis Center at Boston Children’s Hospital and Associate Professor of Pediatrics at Harvard Medical School
“NBD1 is a novel target in Cystic Fibrosis, Clinical Learnings and Research Data”
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial
New preclinical data evaluating NBD1 stabilizers in combination with other CFTR modulators across F508del genotype groups demonstrated the potential of NBD1 stabilizer-based combinations to benefit a broad population of people with CF
Get started
Create a free account to read the full story.